Article Text

Download PDFPDF
PP-007 Stability of diluted and reconstituted antineoplastic drugs: updated 2014
  1. R Guerrero Bautista,
  2. E Ferris Villanueva,
  3. MR Gutiérrez Cívicos,
  4. MH García Lagunar,
  5. A García Márquez,
  6. I Muñoz García,
  7. M Martínez Penella
  1. Hospital General Universitario Santa Lucía, Farmacia Hospitalaria, Cartagena, Spain


Background The lack of studies published on stability of antineoplastic drugs and the contradictory character of the information available increased the need to carry out an internal review in our hospital.

Purpose To investigate the physical-chemical stability of vials of antineoplastic drugs included in the hospital’s Therapeutic Prescription Guide after opening and/or reconstitution.

Material and methods We reviewed all information available in the Spanish Medicines Agency Technical Data Sheets, Micromedex, Stabilis, papers on PubMed and updated guides published by other hospitals in order to establish the physical-chemical stability of these types of drugs.

Results The following storage conditions and maximum storage times were found for 35 cytostatic drugs in use in the hospital: 24 months refrigerated (α 2-B interferon), 90 days at room temperature (RT) (cetuximab), 90 days refrigerated and protected from light (PL) (bevacizumab), 31 days refrigerated PL (pemetrexed), 30 days refrigerated and PL (methotrexate, rituximab, vinorelbine), 28 days at RT (eribulin, etoposide, paclitaxel), 28 days at RT and PL (cisplatin, docetaxel, fluorouracil), 28 days refrigerated (vinblastine), 28 days refrigerated and PL (doxorubicin, pegylated liposomal doxorubicin), 26 days at RT and PL (fludarabine), 22 days refrigerated (mitoxantrone), 21 days refrigerated and PL (carboplatin, ifosfamide), 14 days refrigerated and PL (cyclophosphamide, epirubicin, oxaliplatin, topotecan, mitomycin, vincristine), 8 days frozen with WFI (water for injection) (azacitidine), 7days at RT (carmustine, irinotecan), 7 days refrigerated (cytarabine), 7 days refrigerated and PL (dactinomycin, daunorubicin, gemcitabine, non-pegylated liposomal doxorubicin and idarubicin).

Conclusion The storage protocol was modified for cytostatic vials that had been opened/reconstituted under aseptic conditions using a vertical laminar flow cabin depending on their maximum stabilities. The resulting document was thereafter incorporated into regular working practice. The updated protocol resulted in the medicines being used safely and significant savings on these costly drugs.

References and/or acknowledgements Oncology Department

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.